- Home
- NXC vs ACHV Comparison
NXC vs ACHV Comparison
Compare NXC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXC
- ACHV
- Stock Information
- Founded
- NXC 1992
- ACHV N/A
- Country
- NXC United States
- ACHV United States
- Employees
- NXC N/A
- ACHV N/A
- Industry
- NXC Investment Managers
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NXC Finance
- ACHV Health Care
- Exchange
- NXC Nasdaq
- ACHV Nasdaq
- Market Cap
- NXC 84.3M
- ACHV 72.5M
- IPO Year
- NXC N/A
- ACHV N/A
- Fundamental
- Price
- NXC $12.97
- ACHV $2.31
- Analyst Decision
- NXC
- ACHV Strong Buy
- Analyst Count
- NXC 0
- ACHV 3
- Target Price
- NXC N/A
- ACHV $14.33
- AVG Volume (30 Days)
- NXC 17.5K
- ACHV 1.3M
- Earning Date
- NXC 01-01-0001
- ACHV 08-12-2025
- Dividend Yield
- NXC 3.97%
- ACHV N/A
- EPS Growth
- NXC N/A
- ACHV N/A
- EPS
- NXC 0.19
- ACHV N/A
- Revenue
- NXC N/A
- ACHV N/A
- Revenue This Year
- NXC N/A
- ACHV N/A
- Revenue Next Year
- NXC N/A
- ACHV N/A
- P/E Ratio
- NXC $70.47
- ACHV N/A
- Revenue Growth
- NXC N/A
- ACHV N/A
- 52 Week Low
- NXC $11.86
- ACHV $1.84
- 52 Week High
- NXC $13.70
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- NXC 53.92
- ACHV 39.39
- Support Level
- NXC $12.88
- ACHV $2.02
- Resistance Level
- NXC $13.04
- ACHV $3.90
- Average True Range (ATR)
- NXC 0.13
- ACHV 0.26
- MACD
- NXC -0.00
- ACHV -0.10
- Stochastic Oscillator
- NXC 49.04
- ACHV 17.37
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.